Vertex Pharmaceuticals Stock Forecast, Price & News

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Thursday, April, 29th. The pharmaceutical company reported $2.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.38 by $0.60. The pharmaceutical company had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.66 billion. Vertex Pharmaceuticals had a net margin of 43.06% and a trailing twelve-month return on equity of 29.61%.
View Vertex Pharmaceuticals' earnings history.

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VRTX stock has decreased by 12.4% and is now trading at $193.02.
View which stocks have been most impacted by COVID-19.

Vertex Pharmaceuticals declared that its board has authorized a stock buyback plan on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Vertex Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $6.70 billion-$6.90 billion, compared to the consensus revenue estimate of $6.95 billion.

23 brokerages have issued twelve-month price targets for Vertex Pharmaceuticals' shares. Their forecasts range from $205.00 to $347.00. On average, they expect Vertex Pharmaceuticals' share price to reach $278.60 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts.

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of VRTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.37%), Price T Rowe Associates Inc. MD (6.39%), Alliancebernstein L.P. (3.04%), Capital International Investors (2.33%), Clearbridge Investments LLC (2.13%) and Janus Henderson Group PLC (1.74%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals.

VRTX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, Putnam Investments LLC, Capital International Investors, Thrivent Financial for Lutherans, Fred Alger Management LLC, Assenagon Asset Management S.A., and Man Group plc. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks.

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Canada Pension Plan Investment Board, Ameriprise Financial Inc., ARK Investment Management LLC, Mayflower Financial Advisors LLC, Manning & Napier Group LLC, Point72 Asset Management L.P., and Armistice Capital LLC.
View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks.

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRTX stock can currently be purchased for approximately $193.02.

Vertex Pharmaceuticals has a market capitalization of $49.97 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.

Vertex Pharmaceuticals employs 3,400 workers across the globe.

The following companies are subsidiares of Vertex Pharmaceuticals: Semma Therapeutics.

Vertex Pharmaceuticals was founded in 1989.

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100 or via email at [email protected]